Impact of POR*28 and CYP3A5 polymorphisms on trough concentration to dose ratio of tacrolimus in Thai kidney transplant recipients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20170227005

Enrollment

200

Registered

2017-02-27

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation CYP3A5&#44

Interventions

Adult Thai kidney transplant recipients

Prevention

Tacrolimus

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Eligible patients are those who received tacrolimus for at least 3 months after their kidney transplantation together with mycophenolate mofetil or mycophenolate sodium.

Exclusion criteria

Exclusion criteria: 1) Multi-organ transplantation 2) Hyper-acute graft rejection 3) History of cirrhosis, hepatocelluar carcinoma or hepatitis 4) Severely impaired liver function 5) Hypoalbuminemia (serum albumin <3g/dl) 6) Receiving co-medications that interfere the pharmacokinetic of tacrolimus except for methylprednisolone, prednisolone, and omeprazole

Design outcomes

Primary

Measure	Time frame
trough concentration to dose ratio of tacrolimus blood concentrations Days 3, 7, 90, 180 after transplantation immunoassay	—

Secondary

Measure	Time frame
tacrolimus trough concentrations Days 3, 7, 90, 180 immunoassay	—

Countries

Thailand

Contacts

Public ContactSomratai Vadcharavivad

Chulalongkorn University

somratai@gmail.com66899800694

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026